L3VLUP
ProSign in

ZTS · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ZTSVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ZTS
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterZTSVRTX
Q3 202027 holders, $13.3bn31 holders, $21.9bn
Q4 202025 holders, $13.7bn30 holders, $18.4bn
Q1 202130 holders, $13.9bn31 holders, $15.4bn
Q2 202128 holders, $15.8bn30 holders, $12.7bn
Q3 202129 holders, $16.6bn35 holders, $10.1bn
Q4 202129 holders, $21.1bn28 holders, $12.4bn
Q1 202236 holders, $17.0bn23 holders, $16.1bn
Q2 202237 holders, $15.4bn25 holders, $18.1bn
Q3 202237 holders, $12.9bn22 holders, $18.4bn
Q4 202230 holders, $12.0bn28 holders, $18.4bn
Q1 202324 holders, $13.3bn26 holders, $21.4bn
Q2 202326 holders, $13.3bn27 holders, $24.7bn
Q3 202323 holders, $13.2bn33 holders, $24.3bn
Q4 202319 holders, $14.5bn32 holders, $28.6bn
Q1 202435 holders, $12.2bn31 holders, $29.8bn
Q2 202424 holders, $10.1bn29 holders, $33.4bn
Q3 202424 holders, $9.8bn27 holders, $33.5bn
Q4 202427 holders, $7.7bn26 holders, $28.5bn
Q1 202528 holders, $7.2bn21 holders, $35.4bn
Q2 202526 holders, $6.0bn21 holders, $32.3bn
Q3 202527 holders, $5.9bn22 holders, $25.9bn
Q4 202521 holders, $5.1bn26 holders, $31.8bn
Q1 202621 holders, $4.4bn25 holders, $31.8bn
Q2 202623 holders, $2.7bn26 holders, $34.6bn
ZTS

Zoetis Inc

Holders
21
Reported value
$5.1bn
Buyers
23
Sellers
22

Breadth +1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$31.8bn
Buyers
19
Sellers
20

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 33 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ZTS (7)

AQR Capital Management LLC, Caxton Associates LLP, D. E. Shaw & Co., Freestone Grove Partners LP, Polen Capital Management LLC, Soros Fund Management LLC, Voloridge Investment Management LLC

Only VRTX (12)

ARK Investment Management LLC, Balyasny Asset Management LLC, Capital World Investors, Citadel Advisors LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Marshall Wace LLP, Millennium Management LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →